Renew Clinic Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
At Renew Clinic Sp. z o.o. the dermatology department is advancing therapies for immune‑mediated skin conditions, testing new biologic agents to alleviate disease severity and improve patient quality of life.
- Evaluation of biologic therapy for moderate to severe plaque psoriasis
- Targeted treatment development for hidradenitis suppurativa
- Novel agents aimed at reducing symptoms of atopic dermatitis
The research seeks to demonstrate greater efficacy and safety compared with existing standards, offering patients more effective options for chronic immune skin diseases.
Nutritional and Metabolic Diseases
Clinical studies at the clinic are examining innovative therapies for metabolic disorders, with a focus on improving glycemic control and cardiovascular health in adults with type 2 diabetes.
- Reduction of HbA1c and body weight in type 2 diabetes
- Prevention of major adverse cardiovascular events in patients with type 2 diabetes
These trials aim to provide evidence that new treatments can lower blood sugar levels and reduce heart‑related risks, addressing two of the most pressing challenges in metabolic disease management.
Skin and Connective Tissue Diseases
The dermatology unit conducts a range of investigations into severe skin disorders, evaluating how emerging therapies can lessen disease activity and enhance daily functioning.
- Improvement of severity scores in moderate to severe plaque psoriasis
- Decrease in eczema area and severity index for atopic dermatitis
- Reduction of abscesses and inflammatory nodules in hidradenitis suppurativa
The overarching goal is to validate safer, more effective treatment options that translate into tangible benefits for patients living with chronic skin and connective tissue diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Renew Clinic Sp. z o.o.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa | Bluefin Biomedicine Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 3 | Unknown | 2023-02-28 | 2026-07-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.